Trump’s health department pick has expressed distrust of pharmaceuticals and attacked ‘suppression of psychedelics’. Public health experts are concerned that, if confirmed, Donald Trump’s choice for secretary of the Department of Health and Human Services (HHS) – Robert F Kennedy Jr – could upend access to pharmaceutical drugs in favor of more experimental treatments. Kennedy, who the president-elect picked earlier this month, has repeatedly expressed distrust for pharmaceuticals, and criticized the FDA for its “aggressive…